MET ACTIVATING MUTATION

Clinical trials for MET ACTIVATING MUTATION explained in plain language.

Never miss a new study

Get alerted when new MET ACTIVATING MUTATION trials appear

Sign up with your email to follow new studies for MET ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo aims to shrink tumors before lung cancer surgery

Disease control Not yet recruiting

This study is testing whether adding a targeted drug called Bozitinib to standard chemotherapy helps shrink tumors before surgery for people with a specific genetic change (MET-altered) in their stage IIA-IIIC non-small cell lung cancer. The main goal is to see if this combinatio…

Matched conditions: MET ACTIVATING MUTATION

Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

MET ACTIVATING MUTATION

Get alerted when new MET ACTIVATING MUTATION trials appear

New drug combo aims to shrink tumors before lung cancer surgery